Pacific Edge Limited announced that it had substantially completed a commercial agreement with Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. At this stage the contract remains unsigned. The business case is currently with Te Whatu Ora -Southern Management Team and following that it will enter an approvals cycle.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1 NZD | 0.00% | +2.04% | -14.53% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.53% | 4.97Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- PEB Stock
- News Pacific Edge Limited
- Pacific Edge Limited Completes a Commercial Agreement with Te Whatu Ora Southern